Scientists at Trinity College, Dublin say they have made a major breakthrough in treatment for age-related macular degeneration (AMD) – the leading cause of blindness in people over 50.
Through their research, they have discovered that interleukin-18 (IL-18), a component of the immune system, can protect patients from vision loss, and it can be administered in a non-invasive way. Since current treatments for AMD involve periodically injecting medication directly into the eyeball, this could have significant implications for AMD therapy.
“[IL-18] has already entered into clinical trials [for cancer research], and it has a very good safety profile when administered intravenously. It was never injected into the eye,” study author Matthew Campbell, research assistant professor in genetics at Trinity, told FoxNews.com.
“So all the signs show this could be another tool in the arsenal against wet AMD.”
AMD has two major forms: “dry,” the more common form, and “wet,” which accounts for 90 percent of the severe vision loss caused by macular degeneration. When a patient suffers from wet AMD, the blood vessels grow into the retina, the layer of tissue lining the inner surface of the eye, and begin to leak blood or fluid – causing immediate retinal blindness. Retinal blindness can be especially challenging for patients, as the retina provides sharp, central vision for reading, driving and perceiving small details.
In order to combat wet AMD, patients m? patients must receive them on a monthly basis.
Campbell and his team say IL-18 can work just as effectively as these anti-VEGF injections, as it produces cells that prevent wet AMD.
The Latest on: Age-related macular degeneration
via Google News
The Latest on: Age-related macular degeneration
- This new finding may help in developing treatment for age-related macular degenerationon October 17, 2019 at 7:30 am
A team of scientists has unraveled the molecular mechanism behind the development of age-related macular degeneration (AMD). It has found that it develops because of abnormal activity of a set of ...
- Eye vitamins can fend off macular degenerationon October 17, 2019 at 4:09 am
The goal has been to find which dietary supplements can help fight against age related macular degeneration – a leading cause of blindness for those over 50. And while the goal of the studies has been ...
- Gene-Therapy Treatment May Help People with Macular Degenerationon October 16, 2019 at 3:33 pm
Age-related macular degeneration (AMD) is one of the leading causes of vision loss and blindness among older adults in the United States. But now researchers are looking at a potential new treatment ...
- Trial drug improves vision in age-related macular degenerationon October 16, 2019 at 12:35 am
Patients with “dry” age-related macular degeneration have shown dramatic eyesight improvements in a small phase 2 clinical drug trial. Risuteganib is injected into the eye and is designed to correct ...
- Gene therapy effective for treating wet age-related macular degeneration: Studyon October 14, 2019 at 11:16 pm
Recently developed gene therapy seems to be a promising alternative for treating one of the most common causes of blindness, wet age-related macular degeneration (AMD), claims a study. Researchers ...
- Gene therapy effective for treating macular degeneration: Studyon October 14, 2019 at 6:26 am
Shutterstock. Recently developed gene therapy seems to be a promising alternative for treating one of the most common causes of blindness, wet age-related macular degeneration (AMD), claims a study.
- Gene Therapy Will be Available Soon for Age-related Macular Degenerationon October 14, 2019 at 5:29 am
Gene therapy may be the answer to one of the most common causes of blindness, wet age-related macular degeneration (AMD). Gene therapy is showing promise for one of the most common causes of blindness ...
- In-office gene therapy for wet age-related macular degeneration is comingon October 11, 2019 at 9:03 am
Gene therapy is showing promise for one of the most common causes of blindness. Data presented today shows that six patients with wet age-related macular degeneration (AMD) have, so far, gone at least ...
- Kodiak Sciences Treats First Patients in DAZZLE Pivotal Study of KSI-301 in Wet Age-Related Macular Degenerationon October 10, 2019 at 4:45 pm
Kodiak's lead product candidate, KSI-301, is a novel anti-VEGF antibody biopolymer conjugate being developed for the treatment of retinal vascular diseases including age-related macular degeneration ...
- Quarterly Anti-Vascular Endothelial Growth Factor Dosing for Neovascular Age-Related Macular Degeneration: Real-World Clinical Outcomeson October 8, 2019 at 2:38 pm
Repeated intravitreal injections of anti-vascular endothelial growth factor-A (VEGF) pharmaceuticals are the cornerstone of neovascular age-related macular degeneration (nAMD) management. 1–4 Multiple ...
via Bing News